

### Key Indices Update

Indices	Close	Change (%)
Nifty	24,649.55	0.30▼
Sensex	80,710.25	0.38▼
Midcap	57,206.85	0.39▼
Smallcap	17,864.55	0.16▼

### Trend Strength Indicator

Nifty 50 Stocks above 200 EMA	NSE Advance / Decline
28	1200/1784

### Key Data

Data	Current	Previous
Dow Jones	44,175.9	44,257.7
U.S. Dollar Index	98.82	98.71
Brent Crude (USD/BBL)	67.94	68.82
US 10Y Bond Yield (%)	4.22	4.20
India 10Y Bond Yield (%)	6.37	6.37

### Sectoral Data

Sector	Close	Change (%)
BANKNIFTY	55397.90	0.40▼
NIFTYAUTO	23876.20	0.37↗
NIFTYENERG	34905.65	0.05▼
NIFTYFINSR	28405.55	0.19▼
NIFTYFMCG	55722.30	0.74▼
NIFTYIT	35008.85	0.55▼
NIFTYMEDIA	1638.20	0.18▼
NIFTYMETAL	9336.55	0.09↗
NIFTYPHARM	21952.15	0.91▼
NIFTYREALT	906.35	0.62▼

## Fundamental

Refer Page 02

### Stock for Investment

Stock Name	Sector	*CMP (₹)	^TP (₹)	Upside
SBIN	Banks	801	923	15.3%

\*CMP as on August 05 2025

### Top News

- ✦ **The Anup Engineering Ltd reported robust Q1 FY26 results. Revenue increased by 20% YoY, reaching ₹175 Cr.** EBITDA grew by 22% to ₹40 Cr, with a margin of 23%. PAT (w/o tax reversal) increased by 18%. The company's order book is at ₹604 Cr.
- ✦ **Castrol India announced Q2 FY25 results: Revenue ₹1,497 Cr, up 7% YoY; EBITDA ₹349 Cr, up 8% YoY; PAT ₹244 Cr, up 5% YoY.** 1H FY25: Revenue ₹2,919 Cr, up 7% YoY; PAT ₹477 Cr. Declared ₹3.5/share interim dividend.

## Technical

Refer Page 03-04

- ✦ **Nifty reversed Monday's gains and lost nearly half a percent,** continuing the prevailing corrective trend.
- ✦ After an initial downtick, the **Nifty moved in a narrow range and finally settled at 24,649.55 level.**
- ✦ **Most sectors ended in the red,** with **pharma**, **FMCG**, and **realty** among the top losers.
- ✦ Amid this corrective phase, **select stocks across sectors are showing noticeable strength** and offering buying opportunities.
- ✦ **Participants should therefore maintain a stock-specific approach** and focus on prudent position sizing.
- ✦ **Stock of the day - MAXHEALTH**

## Fundamental

### Top News

01

**Jindal Saw Ltd reported Q1 FY26 results. Standalone total income decreased 25% YoY to ₹33,268 million, with EBITDA down 34% to ₹5,596 million.** PAT declined 18% to ₹3,640 million. Consolidated total income fell 18% YoY to ₹41,030 million, EBITDA decreased 22% to ₹6,883 million, and PAT was ₹4,155 million. The company's order book is ~ \$1,305 million.

02

**The Anup Engineering Ltd reported robust Q1 FY26 results. Revenue increased by 20% YoY, reaching ₹175 Cr.** EBITDA grew by 22% to ₹40 Cr, with a margin of 23%. PAT (w/o tax reversal) increased by 18%. The company's order book is at ₹604 Cr.

03

**Cantabil Retail India announced a final dividend of ₹0.5 per share (25%) for FY25, subject to shareholder approval at the upcoming AGM. The record date for the dividend is Aug 29, 2025.**

04

**Castrol India announced Q2 FY25 results: Revenue ₹1,497 Cr, up 7% YoY; EBITDA ₹349 Cr, up 8% YoY; PAT ₹244 Cr, up 5% YoY.** IH FY25: Revenue ₹2,919 Cr, up 7% YoY; PAT ₹477 Cr. Declared ₹3.5/share interim dividend.

05

**Nitin Spinners Ltd. reported its Q1 FY26 results. Total revenue stood at ₹793.3 Cr, a 1% decrease YoY.** PAT decreased by 2.7% YoY to ₹41.0 Cr. The company is optimistic about the second half of the fiscal year, anticipating better demand.

### Stock for Investment

### State Bank of India

Stock Symbol	SBIN
Sector	Banks
*CMP (₹)	801
^Target Price (₹)	923
Upside	15.3%

\*CMP as on August 05, 2025

^Time horizon - upto 11 Months

- ✦ SBI is a **leading PSU bank** with an **asset size** of ~Rs 42.2 lakhs cr. It has a **market share** of ~19% in **advances** and ~23% in **deposits** as on **Q4FY25**.
- ✦ During **Q4FY25**, it reported a net interest income growth of 2.7% YoY to Rs 42,775 crore, despite a marginal decline in margins on an sequential basis. **Net interest margin saw slight moderation during the quarter as NIM fell by 3 bps QoQ and 25 bps YoY basis. Advances/deposits increased by 12%/9.5% YoY.**
- ✦ The management expects that **credit growth** will by **12%-13% in FY26 slower than earlier guidance on the back of global economy uncertainty**. And they will continue to maintain their market share in deposit franchise.
- ✦ Going forward, **bank** is seeing **improvement** in **asset quality** across **segments** as all the **segments** reported **decline** in **NPA ratio**. The management remains confident about the NIMs to stay above 3% levels despite rate cutting impact.
- ✦ Financially, we expect its NII/PPOP/PAT to grow at a CAGR of 20.5%/13.7%/15.8% over FY25-27E and thus maintain **Buy** with a **target price** of **Rs 923**.

## Technical

**Pause but trend negative. Focus on stock selection.**

### NIFTY

24649.55 ▼ 73.20 (0.30%)

S1

24600

S2

24450


R1

24750

R2

24850

Technical Chart : **Daily**



- ✦ **Nifty reversed Monday's gains and lost nearly half a percent**, continuing the prevailing corrective trend.
- ✦ After an initial downtick, the **Nifty moved in a narrow range and finally settled at 24,649.55 level**.
- ✦ **Most sectors ended in the red**, with pharma, FMCG, and realty among the top losers.
- ✦ Amid this corrective phase, **select stocks across sectors are showing noticeable strength** and offering buying opportunities.
- ✦ **Participants should therefore maintain a stock-specific approach** and focus on prudent position sizing.

### BANKNIFTY

55360.25 ▼ 259.10 (0.47%)

S1

54900

S2

54500


R1

55700

R2

56000

Technical Chart : **Daily**



- ✦ **The banking index declined**, establishing lower lows after breaching its consolidation range and ascending trendline.
- ✦ **Market movement was mixed**; IndusInd Bank, SBI, and Kotak Mahindra Bank outperformed, while ICICI Bank, AU Small Finance Bank, and PNB lost momentum.
- ✦ If the index breaks below the current support at 55,100, **further declines toward the 54,900–54,500 range are anticipated**.
- ✦ On any recovery, **resistance levels are projected at 55,700 and 56,300 (20-day EMA)**.

## Technical

### Stock of the day

**MAXHEALTH**

### Recom.

**BUY**

### CMP (₹)

1273.90

### Range\*

1270-1275


### SL

1225

### Target

1360

### Technical Chart : Daily



- ✦ **Maxhealth is currently trading near its all-time high**, supported by a robust ascending trendline, indicating sustained short-term bullish momentum.
- ✦ **The price action exhibits a higher high and higher low pattern, confirming an uptrend**, with strong support from key short- to medium-term moving averages, notably the 21- and 50-period EMAs.
- ✦ Additionally, the **formation of an inverse head-and-shoulders pattern** further reinforces the bullish continuation signal.
- ✦ **Investors may consider initiating long positions** at recommended entry points.

### Momentum Stocks Midcap

Name	Price	Price %
TANLA	656.20	8.98↗
STLTECH	126.00	6.14↗
NIACL	197.60	5.38↗
MEDPLUS	876.30	4.69↘
TRITURBINE	538.50	8.78↘

### Top 5 F&O Gainers ↗

Name	Price	Price %
SOLARINDS	14940.00	4.00↗
UNOMINDA	1104.00	3.95↗
SIEMENS	3084.90	3.05↗
BHEL	248.50	2.93↗
MAZDOCK	2847.40	2.90↗

### Bullish Charts

Name	Price	Price %
JINDALSTEL	1001.00	2.12↗
NHPC	85.33	2.20↗
PIDILITIND	3003.50	1.75↗
SBILIFE	1860.00	1.56↗
UNOMINDA	1104.00	3.95↗

Name	Price	Price %
BSE	2369.00	4.73↘
NAUKRI	1341.40	2.15↘
ADANIGREEN	972.95	1.70↘
PAGEIND	45735.00	1.15↘
ANGELONE	2598.00	1.13↘

### Range Breakout/ Breakdown

Name	Price	Price %
BSE	2369.00	4.73↘
BRITANNIA	5640.00	2.54↘
IIFL	438.40	2.49↘
BIOCON	373.00	2.46↘
COFORGE	1704.60	2.40↘

### Top 5 F&O Losers ↘

Name	Price	Price %
BSE	2369.00	4.73↘
NAUKRI	1341.00	2.18↘
PAYTM	1053.00	2.34↘
PETRONET	276.90	1.84↘
POLICYBZR	1745.00	2.02↘

### Bearish Charts

## Research Team

Name	Email ID
<i>Ajit Mishra</i>	<a href="mailto:ajit.mishra@religare.com">ajit.mishra@religare.com</a>
<i>Abhijeet Banerjee</i>	<a href="mailto:abhijeet.banerjee@religare.com">abhijeet.banerjee@religare.com</a>
<i>Gaurav Sharma</i>	<a href="mailto:gauravsharma2@religare.com">gauravsharma2@religare.com</a>
<i>Ashwani Harit</i>	<a href="mailto:ashwani.harit@religare.com">ashwani.harit@religare.com</a>
<i>Divya Parmar</i>	<a href="mailto:divya.parmar@religare.com">divya.parmar@religare.com</a>
<i>Vinay Kalani</i>	<a href="mailto:vinay.kalani1@religare.com">vinay.kalani1@religare.com</a>
<i>Rajan Gupta</i>	<a href="mailto:rajan.gupta1@religare.com">rajan.gupta1@religare.com</a>

## Disclaimer

Before you use this research report, please ensure to go through the disclosure inter-alia as required under Securities and Exchange Board of India (Research Analysts) Regulations, 2014 and Research Disclaimer at the following link: <https://www.religareonline.com/disclaimer>

**Specific analyst(s) specific disclosure(s) inter-alia as required under Securities and Exchange Board of India (Research Analysts) Regulations, 2014 is/are as under:**

Statements on ownership and material conflicts of interest, compensation– Research Analyst (RA) [Please note that only in case of multiple RAs, if in the event answers differ inter-se between the RAs, then RA specific answer with respect to questions under F(a) to F(j) below, are given separately]:

S. No.	Statement	Answer	
		Yes	No
	I/we or any of my/our relative has any financial interest in the subject company? <b>[If answer is yes, nature of interest is given below this table]</b>		No
	I/we or any of my/our relatives, have actual/beneficial ownership of one percent. or more securities of the subject company, at the end of the month immediately preceding the date of publication of the research report or date of the public appearance?		No
	I/we or any of my/our relative, has any other material conflict of interest at the time of publication of the research report or at the time of public appearance?		No
	I/we have received any compensation from the subject company in the past twelve months?		No
	I/we have managed or co-managed public offering of securities for the subject company in the past twelve months?		No
	I/we have received any compensation for brokerage services from the subject company in the past twelve months?		No
	I/we have received any compensation for products or services other than brokerage services from the subject company in the past twelve months?		No
	I/we have received any compensation or other benefits from the subject company or third party in connection with the research report?		No
	I/we have served as an officer, director or employee of the subject company?		No
	I/we have been engaged in market making activity for the subject company?		No

Nature of Interest if answer to F(a) above is Yes: ..... Name(s) with Signature(s) of RA(s).

[Please note that only in case of multiple RAs and if the answers differ inter-se between the RAs, then RA specific answer with respect to questions under F(a) to F(j) above, are given below]

SS. No.	Name(s) of RA.	Signatures of RA	Serial Question of question which the signing RA needs to make a separate declaration / answer	Yes	No

Copyright in this document vests exclusively with RBL. This information should not be reproduced or redistributed or passed on directly or indirectly in any form to any other person or published, copied, in whole or in part, for any purpose, without prior written permission from RBL. We do not guarantee the integrity of any emails or attached files and are not responsible for any changes made to them by any other person.

*No representations are being made about the performance or activities unless accompanied by data regarding performance, disclosures of all the risk factors, etc. and disclaimer that "Such representations are not indicative of future results*



